Viewing Study NCT01742793

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:25 AM
Ignite Modification Date: 2026-02-21 @ 7:57 PM
Study NCT ID: NCT01742793
Status: TERMINATED
Last Update Posted: 2020-03-04
First Post: 2012-11-21
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
Sponsor: Yale University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hodgkin's Lymphoma View
None Mature T-cell Lymphoma View
None Multiple Myeloma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None relapsed /refractory Hodgkin lymphoma View
None mature T-cell lymphoma View
None multiple myeloma View